China leads the way in APAC biopharma
With VC deals down across the US and Europe, it’s no surprise that Asia-Pacific also falls well below 2021 highs. APAC healthcare VC deal value has remained consistent at $2.6 billion in Q1, with healthcare companies attracting 16.4% of the region’s VC investment, according to PitchBook’s Q1 2024 APAC Healthcare Market Snapshot.
PE deals have continued to be highlighted by firms such as MBK Partners, Blackstone, and Carlyle finding opportunities in the APAC market.
China is a top target for investors, where companies are capitalizing on opportunities for more affordable medicine. US resistance to drugs manufactured in China could compel businesses to continue to innovate within the country itself.